Strides Arcolab Sells Ascent Generics Unit To Watson For $395 Million
This article was originally published in PharmAsia News
Executive Summary
Strides Arcolab has agreed to sell its Ascent Pharmahealth subsidiary to Watson Pharmaceuticals for more than $395 million.